



FOR IMMEDIATE RELEASE:

**PROFECTUS BIOSCIENCES TO PRESENT NEW DATA AT
12th ANNUAL CONFERENCE ON VACCINE RESEARCH**

Baltimore, MD – April 24, 2009 – Profectus BioSciences, Inc. (Profectus), a clinical stage biopharmaceutical company focused on the development of novel vaccine candidates for chronic viral infections, announced today that the company will present new preclinical data at the 12th Annual Conference on Vaccine Research. The conference is taking place in Baltimore, Maryland from April 27-29, 2009. For more information about the conference, please visit <http://www.nfid.org/conferences/vaccine09/>.

Oral Presentation:

Title: "Plasmid-based IL-12 used in combination with *in vivo* EP and a heterologus pDNA prime, rVSV vector boost vaccination regimen preferentially improves the induction of antigen-specific T cell with a polyfunctional effector memory phenotype in rhesus macaques"

Who: Michael A. Egan, Ph.D., Director of Immunology, Profectus BioSciences

When: Wednesday April 29, 2009 10:30 a.m. - 12:00 p.m.

Where: Harborside Ballroom D, Baltimore Marriott Waterfront Hotel

Poster # P24:

Title: "Protection against heterologous SHIV challenge offered by immunization of Rhesus macaques with a subunit immunogen that mimics the transition state structure presented by CD4 bound HIV envelope"

Who: Timothy R. Fouts, Ph.D., Senior Director of Virology, Profectus BioSciences

Poster # P21:

Title: "The A1 Subunit of Cholera Toxin as an Adjuvant for DNA Vaccines"

Who: Kenneth Bagley, Ph.D., Staff Scientist, Profectus BioSciences

Poster # P23:

Title: "Neurovirulence and Immunogenicity of Highly Attenuated rVSV/HIV-1 Vaccine Vectors in Non-Human Primates"

Who: David Clarke, Ph.D., Director of Vaccine Vectors, Profectus BioSciences

When: Poster sessions are scheduled for Monday, April 27 from 10:00 - 11:30 a.m., and a poster reception will be held on Monday, April 27 at 5:00 p.m.

Where: Posters will remain on display in the Harborside Ballroom D throughout the remainder of the conference until 3:00 p.m. on Tuesday, April 28.

About Profectus BioSciences Inc.

Profectus Biosciences, is an innovative research and development vaccine company devoted to advancing the treatment and prevention of chronic viral diseases. The Profectus proprietary vaccine design approach combines its pDNA and rVSV platforms via a unique prime boost strategy to advance vaccine research. Profectus' broad development pipeline will address Human Immunodeficiency Virus (HIV), Hepatitis C Virus (HCV), Human Papilloma Virus (HPV) and Herpes Simplex Virus (HSV). The Company's first clinical vaccine candidate for human immunodeficiency virus (HIV) is planned for clinical trials in Q4 of 2009 followed by a therapeutic HCV vaccine. The expected data generated from the series of proof-of-concept trials will be useful in the clinical development of vaccine candidates for other indications.

The Profectus portfolio has received over \$100 million in funding from multiple sources including National Institutes of Health (NIH), Cross Atlantic Capital Partners and through private investments. Profectus deploys these resources in support of its proprietary prime boost vaccines and its anti-inflammatory small molecules for cancer and chronic viral diseases. For more information, please visit: <http://www.profectusbiosciences.com>.

#

Contact:

Lisa Rivero

LaVoie Group

978-745-4200 x106

lrivero@lavoiegroup.com

<http://www.lavoiegroup.com>